AC Immune Secures $23M in Milestone Payments, Extends Cash Runway into Q4 2027
Summary
AC Immune announced strong Q1 2026 financial and corporate updates, including significant milestone payments from Takeda and Eli Lilly, and an extended cash runway into Q4 2027, alongside multiple pipeline advancements.
Key Events
-
Secured Significant Milestone Payments
Received a $12 million milestone payment from Takeda for advancing ACI-24 and a CHF10 million upfront payment from Eli Lilly for an amended Morphomer Tau collaboration.
-
Extended Cash Runway
Reported total cash resources of CHF 74.8 million as of March 31, 2026, providing sufficient capital to fund operations into Q4 2027.
-
Advanced Clinical Pipeline
Initiated a Phase 1 trial for the NLRP3 inhibitor ACI-19764 and the final cohort (AD4) for ACI-24 in Alzheimer's Disease.
-
Positive Interim Data Presented
Presented updated interim results from the Phase 2 VacSYn trial for ACI-7104 in Parkinson's disease, showing promising biomarker data.
Analysis
This 6-K provides a highly positive update for AC Immune, significantly de-risking its financial position and highlighting strong progress across its clinical pipeline. The company secured a $12 million milestone payment from Takeda for advancing ACI-24 into its final Phase 1b/2 cohort and a CHF10 million upfront payment from Eli Lilly following an amendment to their Morphomer Tau collaboration. These non-dilutive cash injections, totaling approximately $23 million, are substantial relative to the company's market capitalization. Critically, these funds, combined with existing resources, extend AC Immune's cash runway into Q4 2027, alleviating near-term financing concerns for this clinical-stage biotech. Additionally, the company reported progress on several key programs, including dosing the first subjects in a Phase 1 trial for ACI-19764 and presenting promising interim data for ACI-7104. While one study (ACI-35) has a paused enrollment for a protocol amendment, the overall picture is one of robust operational and financial advancement.
At the time of this filing, ACIU was trading at $3.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $298.2M. The 52-week trading range was $1.51 to $4.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.